KR20150004092A - Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment - Google Patents
Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment Download PDFInfo
- Publication number
- KR20150004092A KR20150004092A KR20130077108A KR20130077108A KR20150004092A KR 20150004092 A KR20150004092 A KR 20150004092A KR 20130077108 A KR20130077108 A KR 20130077108A KR 20130077108 A KR20130077108 A KR 20130077108A KR 20150004092 A KR20150004092 A KR 20150004092A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- ala
- extract
- pdt
- bonnieri
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000002428 photodynamic therapy Methods 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 title claims abstract description 13
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 241001600657 Kalanchoe gastonis-bonnieri Species 0.000 title abstract 3
- 230000003064 anti-oxidating effect Effects 0.000 title description 3
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 30
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008213 purified water Substances 0.000 claims abstract description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 10
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 7
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 6
- 206010000496 acne Diseases 0.000 abstract description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 4
- 229920002674 hyaluronan Polymers 0.000 abstract description 4
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 4
- 235000011187 glycerol Nutrition 0.000 abstract description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 51
- 229960002749 aminolevulinic acid Drugs 0.000 description 50
- 235000006708 antioxidants Nutrition 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 239000012669 liquid formulation Substances 0.000 description 9
- 239000003504 photosensitizing agent Substances 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 230000002165 photosensitisation Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940088033 calan Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
본 발명은 광역동 치료 후처치(PDT)를 위한 칼란코에 추출물이 포함된 항산화 액상 조성물에 관한 것으로서, 보다 상세하게는 여드름 개선 등을 위하여 사용하는 PDT 치료용 ALA 조성물의 적용 시 발생되는 피부의 홍반현상 등의 피부 트러블을 완화시켜주며, 잔존하는 광민감성 물질의 분해 또는 제거해 주는 조성물에 관한 것이다.
The present invention relates to an antioxidant liquid composition containing a calan koa extract for PDT treatment, and more particularly, to an antioxidant liquid composition containing an extract of Kalanco extract for PDT treatment, To a composition which alleviates skin troubles such as erythema and decomposes or removes the remaining photosensitive material.
광역학 치료법(Photodynamic therapy, 이하 'PDT'라 함)이란, 암세포나 각종 종양에 대한 선택성 및 광활성을 가지는 광민감성 물질(photosensitizer)을 이용하여 수술을 시행하지 않고 암 등의 난치병을 치료할 수 있는 기술의 하나로서, 화학요법제와는 달리 부작용이 거의 없는 획기적인 종양치료법이다. Photodynamic therapy (PDT) is a technique that can treat intractable diseases such as cancer without performing surgery by using photosensitizer having selectivity and photoactivity for cancer cells and various tumors. Is a breakthrough tumor treatment that has little side effects unlike chemotherapeutic agents.
최근에는 PDT 치료는 여드름 치료, 개선 등에 널리 사용되고 있다.Recently, PDT treatment has been widely used for acne treatment and improvement.
여드름 치료, 개선 등에 사용되는 PDT 치료에는 레블란 PDT가 있으며, 상기 레블란 PDT에서 레블란이라는 약의 주요 성분은 5-아미노레불린산(5-Aminolevulinic acid, ALA)이다. 그래서 일부에서 그냥 약 성분을 말하고자 ALA PDT라고 칭하기도 한다.In the PDT treatment used for the treatment and improvement of acne, there is Levlan PDT. In the Levlan PDT, 5-Aminolevulinic acid (ALA) is the major component of the drug called levlan. So some of them are called ALA PDT just to say the drug ingredient.
상기 레블란 PDT는 얼굴을 ALA을 함유하는 약(레블란)을 바르고 레이저를 조사하여 여드름균과 피지선을 없애는 치료 시술법이다. The Levantan PDT is a therapeutic procedure that treats facial skin with ALA (levulan) and eliminates acne bacteria and sebaceous glands by laser irradiation.
이와 같이 ALA을 함유하는 레블란을 바르고 레이저를 조사함으로써 여드름 치료 및 개선을 위한 PDT 치료를 시행 후 피부에서 ALA를 함유하는 레블란을 제거하여야 하는데 피부에 흡수된 ALA는 제거되지 않고 피부에 잔존하게 된다.In this way, it is necessary to remove the ALA-containing levan from the skin after applying the levan containing ALA and irradiating it with laser to treat and improve acne. In this case, the ALA absorbed in the skin is not removed and remains on the skin do.
상기와 같이 잔존하는 ALA는 피부를 자극시킴으로써 부작용 즉 홍반 현상 등을 유발시킬 수 있는 문제점이 있다.
The ALA remaining as described above has a problem that it can induce side effects such as erythema by stimulating the skin.
본 발명은 여드름 개선 등을 위하여 사용하는 PDT 치료용 ALA 조성물의 적용시 잔존하는 광민감성 물질을 분해 또는 제거해 주는 중화조성물을 제공하는데 목적이 있다.
It is an object of the present invention to provide a neutralizing composition for decomposing or removing residual photosensitivity substances when applying an ALA composition for treating PDT used for acne improvement and the like.
상기 목적을 달성하기 위한 본 발명인 광역동 치료 후처치를 위한 항산화 액상 조성물은 정제수 64.8중량% ~ 98.8중량%, Ultrez 21 0.2중량% ~ 0.6중량%, To achieve the above object, the present invention provides an antioxidant liquid composition for post-treatment of wide dynamic range, comprising 64.8% to 98.8% by weight of purified water, 0.2% to 0.6% by weight of Ultrez 21,
하이알루론닉애씨드 0.1중량%~ 1.0중량%, 글리세린 0.1중량%~ 20.0중량%, 칼란코에추출물 0.1중량%~ 10.0중량%, 1,2-헥산디올0.5중량%~ 3.0중량%, 트리에탄올아민 0.2중량%~ 0.6중량%로 이루어지는 것을 특징으로 한다.
0.1 wt.% To 1.0 wt.% Of hyaluronic acid, 0.1 wt.% To 20.0 wt.% Of glycerin, 0.1 wt.% To 10.0 wt.% Of extract of calanococcus, 0.5 wt. % To 0.6% by weight.
상기와 같이 이루어지는 본 발명인 광민감성 물질 중화용 액상제형 조성물 실시예 1 내지 3을 이용한 실험과 같이 ALA의 농도가 변화함을 알 수 있듯이 본 발명인 광민감성 물질 중화용 액상제형 조성물은 PDT 치료용 ALA 조성물의 적용시 잔존하는 광민감성 물질을 분해 또는 제거해 주는 효과가 있으며, 이로 인하여 ALA 조성물이 잔존함으로써 발생하는 문제점을 해결할 수 있다.As can be seen from the results of the experiment using the liquid formulation compositions for neutralizing photosensitive materials of Examples 1 to 3 of the present invention as described above, the liquid formulation composition for neutralizing photosensitizers of the present invention was found to contain the ALA composition for PDT treatment Sensitive material, it is possible to solve the problem caused by the remaining ALA composition.
또한, 액상제형으로 이루어짐으로써 피부에 바르기가 쉬우며, 피부에 흡수된 광민감성 물질과 빠르게 반응하여 분해 및 제거할 수 있을 것이다. In addition, since it is a liquid formulation, it is easy to apply to the skin, and it can rapidly react with the photosensitized substance absorbed in the skin to be decomposed and removed.
또한, PDT 처치 후에, 남아있는 ALA농도를 제거함에 있어 홍반 현상 등 PDT 처치에서 발생되는 문제를 칼란코에 함유 중화조성물이 홍반에서 오는 피부 트러블등을 억제하는 효과를 보이고 있다.
In addition, in removing the remaining ALA concentration after PDT treatment, the neutralizing composition containing calanococcus, which is caused by PDT treatment such as erythema phenomenon, has an effect of suppressing skin troubles from erythema.
도 1은 실시예 1에 따른 ALA 조성물에 첨가시 ALA 잔량 변화표
도 2는 실시예 2에 따른 ALA 조성물에 첨가시 ALA 잔량 변화표
도 3은 실시예 3에 따른 ALA 조성물에 첨가시 ALA 잔량 변화표
도 4는 실시예 1에 따른 ALA 조성물에 첨가 후 30분 경과시 ALA 잔량 변화표
도 5는 실시예 2에 따른 ALA 조성물에 첨가 후 30분 경과시 ALA 잔량 변화표
도 6은 실시예 3에 따른 ALA 조성물에 첨가 후 30분 경과시 ALA 잔량 변화표1 is a graph showing changes in ALA residual amount when added to the ALA composition according to Example 1
Fig. 2 is a graph showing the ALA residual amount table when added to the ALA composition according to Example 2. Fig.
Figure 3 is a graph showing the ALA residual amount table when added to the ALA composition according to Example 3
Fig. 4 is a graph showing changes in ALA residual amount at 30 minutes after addition to the ALA composition according to Example 1. Fig.
Figure 5 is a graph showing changes in ALA residual amount at 30 minutes after addition to the ALA composition according to Example 2
Figure 6 is a graph showing changes in ALA residual amount at 30 minutes after addition to the ALA composition according to Example 3
첨부된 도면을 참조로 본 발명의 바람직한 실시 예를 상세히 설명하도록 한다. 이에 앞서, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. Prior to this, terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms, and the inventor should appropriately interpret the concepts of the terms appropriately It should be interpreted in accordance with the meaning and concept consistent with the technical idea of the present invention based on the principle that it can be defined.
따라서, 본 명세서에 기재된 실시 예와 도면에 도시된 구성은 본 발명의 가장 바람직한 일 실시 예에 불과할 뿐 이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해하여야 한다.
Therefore, the embodiments described in the present specification and the configurations shown in the drawings are only the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, It should be understood that various equivalents and modifications may be present.
본 발명의 광역동 치료 후처치를 위한 항산화 액상 조성물은 PDT 치료용 ALA 조성물의 적용시 잔존하는 ALA 농도변화 물질의 구성은 아래 첨부된 표 1과 같이 The composition of the antioxidant liquid composition for post-treatment of photodynamic therapy of the present invention is shown in Table 1 below,
정제수 64.8중량% ~ 98.8중량%, Ultrez 21 0.2중량% ~ 0.6중량%, 64.8% to 98.8% by weight of purified water, 0.2% to 0.6% by weight of Ultrez 21,
하이알루론닉애씨드 0.1중량%~ 1.0중량%, 글리세린 0.1중량%~ 20.0중량%, 칼란코에추출물 0.1중량%~10.0중량%, 1,2-헥산디올0.5중량%~3.0중량%, 트리에탄올아민 0.2중량%~ 0.6중량%으로 구성된다.0.1 wt.% To 1.0 wt.% Of hyaluronic acid, 0.1 wt.% To 20.0 wt.% Of glycerin, 0.1 wt.% To 10.0 wt.% Of extract of calanococcus, 0.5 wt. % To 0.6% by weight.
실시예.Examples.
다음의 표 2와 같은 구성비로 각각 아래와 같이 혼합을 한다. Mix in the following composition ratio as shown in Table 2 below.
제형순서 Formulation sequence
물 -> Ultrez 21(1시간방치)-> 하이알루론닉애씨드 -> 글리세린 -> 칼란코에추출물 -> 1,2-헥산디올 -> 트리에탄올아민
Water -> Ultrez 21 (1 hour left) -> Hyaluronic Acid -> Glycerin -> Calcano extract -> 1,2-Hexanediol -> Triethanolamine
* 상기 표 2의 수치는 중량% 을 의미한다
* The values in the above Table 2 mean% by weight
또한, 상기 표 2의 구성비로 이루어진 각각의 실시예 1 내지 3의 조성물을 이용하여 아래와 같은 방법으로 ALA 농도 변화에 따른 실험을 하였다.Using the composition of each of Examples 1 to 3 having the composition ratios shown in Table 2, an experiment was performed according to ALA concentration change as follows.
1. 각 실시예에 따라 상기 PDT 시술에 사용되는 광민감성 중화조성물 1㎖를 PDT 치료용 15% ALA 조성물 10㎖에 넣고 볼텍스(Voltex)한다. 1. According to each example, 1 ml of the photosensitizing neutralizing composition used in the PDT procedure is placed in 10 ml of a 15% ALA composition for PDT treatment and vortexed.
2. 상기 1의 볼텍스(Voltex)한 조성물을 소량 sampling하여 99배 희석한다.(0.1% 농도 기준으로 한다.)2. A small amount of the above Voltex 1 composition is diluted 99 times (based on 0.1% concentration).
3. 10㎖ test tube에 1M Acetate Buffer(pH 4.7) 1㎖에 상기 2번의 희석된 sample 20㎕, 0.1㎖ Methylacetoacetate를 넣고 vortex한다. 3. In 1 ml of 1M Acetate Buffer (pH 4.7) in a 10 ml test tube, add 20 μl of the 2 diluted samples and 0.1 ml of Methylacetoacetate to the vial.
4. 10분간 90℃로 Heating한 후 상온(15℃)으로 냉각한다.4. Heat at 90 ° C for 10 minutes and cool to room temperature (15 ° C).
5. 2㎖ Ehrlich's reagent 를 넣고 섞는다(vortex). 5. Add 2 ml Ehrlich's reagent and mix (vortex).
6. 10분 후에 UV 스펙트럼을 이용, ALA의 잔량을 조사하여 기존 농도에서 ALA 농도와 중화조성물을 첨가 후에 ALA의 잔량을 측정, 도시하였다.
6. After 10 minutes, the remaining amount of ALA was measured using UV spectrum, and the remaining amount of ALA was measured after addition of ALA concentration and neutralizing composition at the existing concentration.
도 1은 실시예 1의 구성비로 이루어진 광민감성 물질 중화용 액상제형 조성물을 PDT 시술에 사용되는 ALA 조성물에 첨가시 ALA 잔량 변화표이며, FIG. 1 is a graph showing the ALA residual amount when the liquid formulation composition for neutralizing photosensitizing substances in Example 1 is added to the ALA composition used in the PDT procedure,
도 2는 실시예 2의 구성비로 이루어진 광민감성 물질 중화용 액상제형 조성물을 PDT 시술에 사용되는 ALA 조성물에 첨가시 ALA 잔량 변화표이며,FIG. 2 is a graph showing the ALA residual amount when the liquid formulation composition for neutralizing photosensitizing substances in the composition ratio of Example 2 is added to the ALA composition used in the PDT procedure,
도 3은 실시예 3의 구성비로 이루어진 광민감성 물질 중화용 액상제형 조성물을 PDT 시술에 사용되는 ALA 조성물에 첨가시 ALA 잔량 변화표이다.FIG. 3 is a table showing the ALA residual amount when the liquid formulation composition for neutralizing photosensitizing substances comprising the composition ratio of Example 3 is added to the ALA composition used in the PDT procedure.
상기 도 1 내지 도 3의 그래프에서와 같이 조성물 첨가후에 ALA 농도잔량이 기준 대비하여 남지 않는 것을 알 수 있는 것으로서, ALA 농도변화에 따른 항산화 조성물인 실시예 1내지 3를 첨가하면, ALA농도는 기준 대비하여 53% 내지 20%의 ALA농도 잔량이 남아있는 것을 확인할 수 있는 것으로서, 본 발명의 조성물이 ALA 농도 잔량에 효과가 있음을 알 수 있는 것이다.As shown in the graphs of FIGS. 1 to 3, it can be seen that the remaining amount of ALA concentration does not remain after the addition of the composition. When the antioxidative compositions Examples 1 to 3 according to the ALA concentration change are added, It can be confirmed that the residual amount of ALA concentration of 53% to 20% remains as compared with that of the composition of the present invention.
도 4는 실시예 1의 구성비로 이루어진 광민감성 물질 중화용 액상제형 조성물을 PDT 시술에 사용되는 ALA 조성물에 첨가 후 30분 경과시 ALA 잔량 변화표이며, FIG. 4 is a table showing ALA residual amounts at 30 minutes after the addition of the liquid formulation composition for neutralizing photosensitivity to the ALA composition used in the PDT procedure,
도 5는 실시예 2의 구성비로 이루어진 광민감성 물질 중화용 액상제형 조성물을 PDT 시술에 사용되는 ALA 조성물에 첨가 후 30분 경과시 ALA 잔량 변화표이며, FIG. 5 is a table showing ALA residual amounts at 30 minutes after addition of the liquid formulation composition for photosensitizing substance neutralization comprising the composition ratio of Example 2 to the ALA composition used in the PDT procedure,
도 6은 실시예 3의 구성비로 이루어진 광민감성 물질 중화용 액상제형 조성물을 PDT 시술에 사용되는 ALA 조성물에 첨가 후 30분 경과시 ALA 잔량 변화표이다. FIG. 6 is a table showing ALA residual amounts at 30 minutes after addition of the liquid formulation composition for photosensitizing substance neutralization comprising the composition ratio of Example 3 to the ALA composition used in the PDT procedure.
상기 도 4 내지 도 6의 그래프에서와 같이 시간이 경과한 후에도 ALA 잔량이 남지 않는 것을 알 수 있는 것으로서, ALA 농도변화에 따른 항산화 조성물인 실시예 1내지 3를 첨가하면, ALA농도는 기준 대비하여 26% 내지 13%의 ALA농도 잔량이 남아있는 것을 확인할 수 있는 것으로서, 본 발명의 조성물이 ALA 농도 잔량에 효과가 있음을 알 수 있는 것이다.As shown in the graphs of FIGS. 4 to 6, it can be seen that no residual ALA remains after a lapse of time. When the antioxidative compositions Examples 1 to 3 according to ALA concentration were added, the ALA concentration It can be confirmed that a residual amount of ALA concentration of 26% to 13% remains, and it is understood that the composition of the present invention has an effect on the residual ALA concentration.
또한, PDT 처치 후에, 남아있는 ALA농도를 제거함에 있어 홍반 현상 등 PDT 처치에서 발생되는 문제를 칼란코에 함유 중화조성물이 홍반에서 오는 피부 트러블등을 억제하는 효과를 보이고 있으며, 이를 위하여 칼란코에를 함유한 조성물이 항산화물질에도 뛰어난 효과를 보이고 있는 것에 대한 실험값은 다음과 같다.In addition, in removing the residual ALA concentration after PDT treatment, the neutralizing composition containing calanococcus, which is caused by the treatment of PDT such as erythema, has an effect of suppressing skin troubles from erythema, The experimental values for the excellent antioxidative effect of the composition containing the antioxidant are as follows.
항산화물질의 가장 큰 특징적인 기작은 유리기와 반응하는 것으로 유리기 소거작용은 활성라디칼(free radical)에 전자를 공여하여 식물 중의 항산화 효과나 인체에서의 노화를 억제하는 척도로 사용된다. The most distinctive mechanism of antioxidants is to react with free radicals. The free radical scavenging function is used as a measure to inhibit the antioxidative effect and the aging in the human body by donating electrons to free radicals.
다음 실험에서는 칼란코에 추출물이 포함된 상기 실시예 1 내지 3이 가지는 항산화 효능을 검증하기 위해 DPPH법을 이용하여 항산화할성을 측정한다.In the following experiment, antioxidative properties were measured using the DPPH method in order to verify the antioxidative effects of the above Examples 1 to 3 containing extracts of calanococcus.
각 조성물 40㎕를 300μM DPPH/EtOH 760㎕에 첨가한 후 30분간 37℃에서 방치한 후 UV/Vis spectrophotometer(GENESYS 10S Vis Spectrophotometer)을 이용하여 518nm에서 흡광도를 측정한다. 40 μl of each composition is added to 760 μl of 300 μM DPPH / EtOH, and the mixture is allowed to stand at 37 ° C. for 30 minutes. Absorbance is measured at 518 nm using a UV / Vis spectrophotometer (GENESYS 10 S Vis Spectrophotometer).
항산화 활성도출을 위한 실험식은 다음과 같다.The empirical formula for deriving antioxidant activity is as follows.
이를 위하여 각각의 조성물에 흡광도를 측정하여, 각각의 항산화도를 도출하는 것이다.For this purpose, the absorbance of each composition is measured to derive the respective antioxidant levels.
항산화도(%)={1-(항산화물질 첨가구의 흡광도)/(항산화물질 무 첨가구의 흡광도)}×100(%) = {1- (absorbance of the antioxidant-added sphere) / (absorbance of the antioxidant-free sphere)} x 100
각각의 조성물에 대하여 상온과 50°C , 2가지 온도조건에서 대략 1주일 간격으로 4번의 기간에 걸쳐, 비교대상과 함께 동일한 조건으로 실험측정한 결과는 표3에 제공한다.
Table 3 shows the results of experimental measurements of the respective compositions at the room temperature and 50 ° C, four times at two temperature conditions, at intervals of about one week, under the same conditions with the comparative objects.
<실험식에 근거한 비타민 C(1% 수용액) 대비 결과값>
<Result of vitamin C based on empirical formula (1% aqueous solution)>
상기 표 3의 실험결과에 의하면, 본 발명의 조성물들은 최초 실험일로부터 시간이 경과함에 따라, 비교예인 H사 항산화물질에 대비하여, 상온에서는 최대 7배이며, 50°C에서는 최대 4배정도의 항산화도를 나타내고 있다.According to the results of the experiment of Table 3 above, the compositions of the present invention show antioxidant activity of up to 7 times at room temperature and up to 4 times of antioxidant at 50 ° C, Fig.
또한, 표 3을 살펴보면, 상온에서 3가지 조성물인 본 발명과 비교예와의 항산화도 실험값 비교를 나타낸 것으로서, 이를 살펴보면, 본 발명인 조성물들은 기간이 경과함에 따라서도 항산화도의 변화가 최초 시간 대비하여 40% 감소하고 있으나, 비교예인 경우에는 80% 감소한 항산화도를 보이고 있다.As shown in Table 3, the antioxidative activities of the three compositions of the present invention and the comparative examples at room temperature were compared. As a result, the compositions of the present invention showed that changes in antioxidant ability 40%, whereas in the case of the comparative example, the degree of antioxidation decreased by 80%.
또한, 표 3을 살펴보면, 50°C에서 3가지 조성물인 본 발명과 비교예와의 항산화도 실험값 비교를 나타낸 것으로서, 상기 상온에서와 같이, 비교예인 시중의 항산화제품에 비하여 기간이 경과한 경우에라도, 항산화도의 감소에 상대적으로 좋은 결과를 나타내고 있다. 또한, 비교예의 항산화도에서 동일한 시점에서, 최대 3.8배의 항산화도 효능이 높은 것으로 나타나고 있으며, 이러한 경향은 시간이 경과함에 따라서, 비교예에 비하여, 항산화 물질의 안정성이 높음을 알 수 있다. As shown in Table 3, the antioxidative activity of the three compositions of the present invention and the comparative example at 50 ° C is also compared with that of the comparative example. , And the antioxidant activity was relatively good. In addition, the antioxidant activity of the comparative example showed a high antioxidative effect at a maximum of 3.8 times at the same time point, and this tendency shows that the stability of the antioxidant substance is higher than that of the comparative example over time.
본 발명인 조성물인 경우에는 비교예에 비하여, 기간이 경과하여도 최초 값에 비교하여, 항산화도의 감소폭이 매우 적은 것으로, 기간경과에 대하여 매우 안정적인 항산화도 값을 나타내고 있으며, 이는 사용상에 따른 항산화 효능에 있어서 매우 중요한 척도인 것이다.Compared with the comparative example, the composition of the present invention shows a very stable antioxidant value with respect to the elapsed time since the decrease in the degree of antioxidation is very small compared to the initial value even after the lapse of the period, It is a very important measure in
또한, 비타민 C는 측정 시 검사시료의 안정성을 검증하기 위해 측정한 결과값이며, 칼란코에 추출물 원액의 결과값을 보면 상온과 고온안정성이 좋아 화장품 등의 제형으로 사용할 수 있음을 알 수 있었으며, 이에 항산화물질로서 칼란코에 추출물이 포함된 항산화물은 상온과 고온에서 활성화도를 측정한 결과 비교예인 시중의 항산화 물질 첨가형 제품과 비교하여 우수함을 보이고 있음을 알 수 있다.In addition, vitamin C was measured in order to verify the stability of the test sample in the measurement, and the result of the crude extract of calanococcus was found to be good for room temperature and high temperature stability, The antioxidative activity of carang koe extract as an antioxidant was found to be superior to those of the antioxidant supplemented product, which is a comparative example, when the activity was measured at room temperature and high temperature.
Claims (2)
하이알루론닉애씨드 0.1중량%~ 1.0중량%, 글리세린 0.1중량%~ 20.0중량%, 칼란코에추출물 0.1중량%~10.0중량%, 1.2-헥산디올0.5중량%~3.0중량%,
트리에탄올아민 0.2중량%~ 0.6중량%의 조성물로 이루어지는 광역동 치료 후처치(PDT)를 위한 칼란코에 추출물이 포함된 항산화 액상 조성물.
Purified water 64.8 wt% to 98.8 wt%, Ultrez 21 0.2 wt% to 0.6 wt%
0.1% by weight to 10.0% by weight of extract of calanococcus, 0.5% by weight to 3.0% by weight of 1,2-hexanediol, 0.1%
An antioxidant liquid composition comprising a carang koe extract for photodynamic therapy (PDT) comprising 0.2% to 0.6% by weight of a composition of triethanolamine.
상기 조성물은 액상제형으로 이루어짐으로써 피부에 바르기가 쉬우며, 피부에 흡수된 광민감성 물질과 빠르게 반응하여 분해 및 제거할 수 있는 특징을 포함하도록 이루어지는 광역동 치료 후처치(PDT)를 위한 칼란코에 추출물이 포함된 항산화 액상 조성물.The method according to claim 1,
(PDT), which is characterized in that the composition is in a liquid form and is easy to apply to the skin and is capable of rapidly reacting with and decomposing and removing the photosensitized substance absorbed in the skin, Gt; antioxidant < / RTI >
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130077108A KR20150004092A (en) | 2013-07-02 | 2013-07-02 | Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment |
| PCT/KR2013/009510 WO2015002347A1 (en) | 2013-07-02 | 2013-10-24 | Liquid-phase antioxidant composition comprising kalanchoe extract for after-treatment following photodynamic therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130077108A KR20150004092A (en) | 2013-07-02 | 2013-07-02 | Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150004092A true KR20150004092A (en) | 2015-01-12 |
Family
ID=52143908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20130077108A KR20150004092A (en) | 2013-07-02 | 2013-07-02 | Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20150004092A (en) |
| WO (1) | WO2015002347A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6812153B2 (en) * | 2016-07-19 | 2021-01-13 | 花王株式会社 | Absorber manufacturing equipment and absorber manufacturing method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4880816B2 (en) * | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | Skin anti-aging agent |
| CA2457214A1 (en) * | 2004-02-06 | 2005-08-06 | Qlt Inc. | Photodynamic therapy for the treatment of acne |
| GB0700580D0 (en) * | 2007-01-11 | 2007-02-21 | Photocure Asa | Use |
| KR101308652B1 (en) * | 2011-05-19 | 2013-09-13 | 제너럴바이오(주) | Liquid composition for neutralize acne |
| KR101321950B1 (en) * | 2011-05-19 | 2013-10-28 | 제너럴바이오(주) | Liquid composition for neutralize photosensitizer |
-
2013
- 2013-07-02 KR KR20130077108A patent/KR20150004092A/en not_active Application Discontinuation
- 2013-10-24 WO PCT/KR2013/009510 patent/WO2015002347A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015002347A1 (en) | 2015-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030147937A1 (en) | Use of compatible solutes as substances having free radical scavenging properties | |
| Vostalova et al. | Lonicera caerulea fruits reduce UVA-induced damage in hairless mice | |
| KR100968908B1 (en) | Cosmetic composition containing electro-analysised water of nano platinum colloid | |
| Saini et al. | Evaluation of radioprotective efficacy and possible mechanism of action of Aloe gel | |
| CN105030622B (en) | A kind of lightening compositions and preparation method thereof | |
| Chougule et al. | In-Vitro antioxidant activity of ethanolic extract of Centaurea behen | |
| KR101892079B1 (en) | Composition for improving acnes and kit for improving acnes containing the same | |
| JP2015529241A5 (en) | ||
| KR20150004092A (en) | Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment | |
| KR101321950B1 (en) | Liquid composition for neutralize photosensitizer | |
| WO2012105632A1 (en) | External skin preparation | |
| TWI524892B (en) | Use of ugonin compounds for manufacturing compositions for anti-inflammation in skin | |
| CN107773487A (en) | A kind of radiation proof is dispelled yellow cleawhite pack | |
| Shin et al. | Anti-Photoagaing and Photo-Protective Compounds from Marine Organisms | |
| Arct et al. | Disadvantages of organic UV filters | |
| JP2006315957A (en) | Singlet oxygen scavenger and external preparation for skin using the same | |
| CN105362676A (en) | Preparation method and application of traditional Chinese medicine composition having multiple effects for skin care | |
| Denis et al. | Evaluation of the Stimulating and Protective Effects of Fucoxanthin Against Human Skin Fibroblasts: An In Vitro Study | |
| JP6671832B2 (en) | Heat shock protein expression inducer | |
| TWI624265B (en) | Use of dipsacus asper wall extract for manufacturing compositions to inhibit oxidation for anti aging skin | |
| TW201620536A (en) | Anti-inflammatory composition | |
| Yan et al. | Levels of retinyl palmitate and retinol in the skin of SKH-1 mice topically treated with retinyl palmitate and concomitant exposure to simulated solar light for thirteen weeks | |
| KR101308652B1 (en) | Liquid composition for neutralize acne | |
| Thevanayagam et al. | Photoprotective effects of carrageenans against ultravioletb-induced extracellular matrix (ECM) damage in keratinocytes | |
| KR102396785B1 (en) | Antioxidant complex and composition forming the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |